Figure 1.

Schematic representation of decision matrix for short-term objectives (3 years). ctivities related to trials of selected combination of anti-parasitic drugs will proceed in parallel with development of immuno-chemotherapy approach using available drugs, immun-modulators, with or without leishmanial antigens. Efforts will be focused on enhancing the quality of clinical trials through development of standard protocols and ICH-GCP training.